Skip to main content

Latest news


Catch up with the latest research news, approvals, and guideline updates in oncology.


More breast cancer news

Young girl having ECG

31-05-2023 | Cardiotoxicity | News

Anthracyclines may increase heart failure risk among YA cancer survivors

Anthracycline exposure in young adults who previously received cancer treatment is associated with a significantly elevated risk for heart failure.

05-05-2023 | Breast cancer | News

DESTINY-Breast02 supports T-DXd as ‘preferred’ regimen after progression on T-DM1

Patients with HER2-positive metastatic breast cancer that is refractory or resistant to trastuzumab emtansine have significantly better outcomes with trastuzumab deruxtecan than a physician’s choice treatment, shows the phase 3 DESTINY-Breast02 trial.

Pregnant woman on drip

24-04-2023 | Pregnancy | News

Increased 5-year mortality risk for cancers diagnosed during pregnancy, postpartum

Pregnancy-associated cancers may be linked to an elevated 5-year mortality risk, but the risk varies by tumor site and time of diagnosis, suggests a population-based cohort study.

06-04-2023 | Breast cancer | News

Anthracycline-related heart failure risk highlighted for breast cancer, lymphoma survivors

Research has confirmed that congestive heart failure is significantly more common in people given an anthracycline to treat breast cancer or lymphoma than among those given other types of chemotherapy, even after adjusting for confounding factors.

Genitourinary cancers news

08-08-2023 | Renal cell carcinoma | News

Potential of pembrolizumab plus lenvatinib for non-clear-cell RCC shown

The combination of pembrolizumab and lenvatinib has durable antitumor activity and promising survival outcomes in treatment-naïve patients with advanced non-clear-cell renal cell carcinoma, say the KEYNOTE-B61 investigators.

Patient taking tablets

30-06-2023 | Prostate cancer | News

First-line talazoparib plus enzalutamide supported for mCRPC

Adding talazoparib to enzalutamide significantly improves the outcomes of untreated patients with metastatic castration-resistant prostate cancer, regardless of homologous recombination repair mutation status, shows the TALAPRO-2 trial.

More genitourinary cancers news

Young girl having ECG

31-05-2023 | Cardiotoxicity | News

Anthracyclines may increase heart failure risk among YA cancer survivors

Anthracycline exposure in young adults who previously received cancer treatment is associated with a significantly elevated risk for heart failure.

Transgender symbol

09-05-2023 | Prostate cancer | News

Prostate cancer in transgender women ‘not so rare’

A chart review of the Veterans Affairs health system indicates that there are around 14 cases of prostate cancer per year among transgender women.

29-03-2023 | Prostate cancer | News

ProtecT 15-year results: Prostate cancer-specific mortality ‘low’ irrespective of treatment

The 15-year data from the ProtecT trial show low rates of prostate cancer-specific mortality among men with prostate-specific antigen-detected, localized disease regardless of whether they received active monitoring, prostatectomy, or radiotherapy.

08-03-2023 | EMA | News

EMA backs niraparib–abiraterone dual-action tablet for mCRPC

Read more about this decision here

Lung & thoracic cancers news

29-09-2023 | Adverse events | News

Trial adds to evidence for risk-based thromboprophylaxis in people with cancer

Findings from the TARGET-TP trial support a risk-directed approach to thromboprophylaxis in ambulatory patients with gastrointestinal or lung cancer receiving systemic anticancer treatment.

22-09-2023 | KRAS inhibitors | News

Novel KRAS inhibitor elicits ‘durable responses’ in KRAS G12C mutation-positive tumors

The novel KRAS inhibitor divarasib has shown promise in previously treated patients with advanced solid tumors harboring a KRAS G12C mutation.

More lung & thoracic cancers news

13-09-2023 | Immunotherapy | News

Cutaneous irAEs tied to improved survival after ICI treatment

A meta-analysis has shown that cutaneous immune-related adverse events are prognostic for improved survival among people with cancer receiving immune checkpoint inhibitor therapy.

08-09-2023 | Non-small-cell lung cancer | News

Add-on tumor treating fields boost metastatic NSCLC survival

Supplementing standard systemic therapy with tumor treating fields prolongs the overall survival of previously treated patients with metastatic NSCLC.

Stay informed with Medicine Matters

Get the latest developments in breast, lung, & GU cancers delivered straight to your inbox


The Medicine Matters news service is brought to you in partnership with medwireNews